Overview of Codopalm

Property	Description
Active ingredient	Promethazine hydrochloride
Form	Tablet, syrup, suppository, injection
Pharmacological class	First-generation antihistamine (H1 antagonist)
General purpose	Allergy relief, sedation, antiemetic effect
Origin	Synthetic compound

Codopalm is a pharmaceutical preparation containing the active ingredient Promethazine hydrochloride, which is recognized as a potent first-generation antihistamine and a phenothiazine derivative. It is a synthetic compound that works by antagonizing multiple receptor types, thereby influencing various central nervous system functions.

Identity and Pharmacological Classification

Codopalm is fundamentally identified as a phenothiazine-class drug that functions as an H1 receptor antagonist. This means the medication helps to counteract the effects of histamine released during allergic responses. The characteristic of Promethazine is its ability to cross the blood-brain barrier effectively, resulting in potent central nervous system effects. This multi-receptor activity gives it secondary actions, classifying it additionally as a sedative-hypnotic agent. The medicine has a significant potential to induce sleepiness.

Composition, Forms, and General Therapeutic Purpose

The medicine is composed of Promethazine hydrochloride as the sole active substance, offered in various formulations for different routes of administration. It is commonly prepared in solid forms, such as the tablet and suppository for rectal use, as well as in liquid forms like oral solution (syrup) and a sterile parenteral preparation for injection. Its general therapeutic purpose is threefold: the control of nausea and vomiting (antiemetic effect), the facilitation of short-term sedation—such as for pre-operative calming—and the alleviation of symptoms stemming from histamine release. Promethazine's classification as a highly sedating antihistamine differentiates it from newer, less potent H1 blockers.

Regulatory References

NIH StatPearls

What side effects are possible with Codopalm?

Possible side effects and safety information

Codopalm (Promethazine hydrochloride) is associated with an official safety profile defined by its classification as a potent first-generation antihistamine and phenothiazine derivative. Side effects are formally grouped and classified by frequency and by affected physiological system in regulatory documents.

Common Adverse Reactions

The most frequently documented adverse reactions, which are classified as Common or Very Common in official prescribing information, primarily involve the Nervous System. These effects include pronounced sedation, drowsiness, dizziness, and incoordination. Additionally, anticholinergic effects such as dry mouth and blurred vision are frequently reported.

System-Organ Classes and Serious Adverse Reactions

Adverse reactions may affect other system-organ classes, including the Gastrointestinal (constipation), Vascular (hypotension), and Skin systems (photosensitivity). The regulatory label also documents specific, Serious Adverse Reactions, which are classified as Rare or Very Rare. These include Respiratory Depression, Neuroleptic Malignant Syndrome (NMS), and severe Bone Marrow Depression (e.g., agranulocytosis).

Safety Considerations for Specific Populations

Specific restrictions define the use of this medicine in certain groups. Promethazine is absolutely contraindicated for use in children under two years of age due to the risk of potentially fatal respiratory depression. Additionally, official documents note that older adults may have heightened sensitivity to the anticholinergic and hypotensive effects. Due to the pronounced sedative nature of the drug, regulatory safety statements explicitly constrain its use in situations that require full mental alertness and physical coordination.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Codopalm (Promethazine hydrochloride) is associated with a wide and variable range of clinical signs, all of which require immediate medical attention. Officially documented manifestations include significant disturbances of the Central Nervous System (CNS), which may present as deep drowsiness and coma in adults, contrasting with excitation, hallucinations, restlessness, and seizures commonly observed in children. Other documented signs of toxicity include an anticholinergic syndrome, characterized by symptoms such as dilated pupils, dry mouth, and urinary retention, alongside systemic effects like rapid heartbeat (tachycardia) and low blood pressure (hypotension).

Regulators underscore the potential for severe or life-threatening outcomes. These include the risk of fatal respiratory depression, which is a particular concern and a key reason for the drug's contraindication in children under two years of age. Serious outcomes such as life-threatening cardiac arrhythmias and the development of Neuroleptic Malignant Syndrome (NMS) are also documented.

Because no specific pharmacological antidote is known, official guidance mandates immediate medical attention for all suspected overdose situations. Management involves providing symptomatic and supportive treatment, with critical attention given to maintaining adequate respiratory and circulatory function, as detailed in regulatory documents. Urgent help must be sought if the individual has collapsed, cannot be awakened, or is experiencing difficulty breathing.

Therapeutic Uses of Codopalm

Codopalm is applied across domains where additional symptomatic support is needed, addressing symptom clusters that may become intense or disruptive in conditions characterized by acute or episodic manifestations. The medication is commonly used to help with symptomatic relief for allergies, to assist with symptoms of nausea and vomiting, and to support short-term sedation.

The medication is relevant for easing challenging symptoms, such as the intense itching (pruritus) and upper respiratory symptoms like sneezing and runny nose associated with allergic distress, and for easing symptoms of nausea and vertigo linked to motion sickness or postoperative states. For patients facing procedures, the agent is used when short-term symptomatic assistance is needed to promote calm and facilitate light rest.

“It is relevant across contexts marked by increased discomfort or tension, providing supportive relief when symptoms interfere with routine activities.”

Quick Fact: Therapeutic Support

The therapeutic benefit generally assists with improved comfort by easing the overall burden of symptoms related to systemic imbalance and heightened physiological activity, and may assist patients in coping with difficult episodes.

Eligibility and Restrictions for Use

The eligibility for using Codopalm (Promethazine hydrochloride) is strictly defined by regulatory warnings concerning age, underlying medical conditions, and physiological status.

Populations for Whom Use is Contraindicated

Codopalm must not be used in the following populations, as formally stated in regulatory documents:

Pediatric patients younger than two years of age due to the potentially fatal risk of respiratory depression.
Individuals in a comatose state.
Patients with a known hypersensitivity to promethazine or any other phenothiazine derivative.
For treating lower respiratory tract symptoms, including asthma.

Age and Condition-Based Restrictions

Population Group / Status	Official Regulatory Stance
Pediatric patients ge 2 years	Use is permitted, but caution is mandatory due to the risk of respiratory depression. Use should be avoided in children with signs suggesting Reye's syndrome or hepatic disease.
Older Adults (ge 65 years)	Use is generally not recommended due to increased sensitivity to adverse effects, including confusion and falls.
Pregnancy	Use is limited; generally only if the potential benefit justifies the potential risk. Avoidance is advised in the two weeks prior to delivery.
Breastfeeding	Not recommended due to the potential for adverse effects in the nursing infant.
Specific Medical Conditions	Use requires caution in patients with cardiovascular disease, liver function impairment, seizure disorders, narrow-angle glaucoma, or conditions causing urogenital or gastrointestinal obstruction (e.g., prostatic hypertrophy).
Compromised Breathing	Should be avoided in patients with compromised respiratory function (e.g., COPD, sleep apnea).

What should I know about interactions with other medicines?

Codopalm contains promethazine, a sedating antihistamine, and should be used with caution due to the risk of significant interactions. The most important interactions involve medicines that also cause Central Nervous System (CNS) depression or have anticholinergic effects.

️ Increased CNS Depression

Combining Codopalm with other CNS depressants can lead to excessive drowsiness, sedation, respiratory depression, and potentially coma or death. Avoid or use with extreme caution alongside:

Opioid Painkillers: Such as morphine, hydrocodone, or oxycodone.
Benzodiazepines: Medicines for anxiety or sleep, such as diazepam, lorazepam, or alprazolam.
Alcohol: Consumption of alcohol must be avoided, as it significantly increases the sedative and respiratory depressant effects.
Other Sedatives: Including other antihistamines (like diphenhydramine), general anesthetics, tricyclic antidepressants, and barbiturates like phenobarbital.

Other Notable Interactions

Type of Medicine	Effect of Interaction
Monoamine Oxidase Inhibitors (MAOIs) (or use within 14 days of stopping them)	Can increase the anticholinergic effects of promethazine and the risk of extrapyramidal symptoms.
Anticholinergic Agents (e.g., some bladder, eye, and respiratory medicines)	Increased risk of side effects like dry mouth, blurred vision, constipation, and urinary retention.

Always inform your healthcare provider of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking before starting Codopalm.

Mechanism of Action

Codopalm is a combination product that exerts its action through the distinct pharmacological mechanisms of its two active components. The drug engages multiple signaling pathways, primarily modulating overactive processes in the central nervous system (CNS) and peripheral systems, which results in changes to local and systemic physiological activity.

H1-Receptor Antagonism

Promethazine, one component, functions as a competitive antagonist at histamine H1 receptors across various tissues. By competitively binding to these receptors, this mechanism prevents the effects of endogenous histamine, thereby modifying early molecular steps that influence physiological responses and systemic outcomes.

Central Opioid Receptor Modulation

Codeine, the second component, acts as an opioid agonist, primarily binding to and activating mu-opioid receptors in the CNS. This activation initiates signaling cascades that modulate neurotransmission within pathways associated with afferent signaling and efferent airway reflexes.

Anticholinergic and Antidopaminergic Effects

Promethazine further modulates key pathways through its antagonistic activity at muscarinic acetylcholine receptors and mesolimbic dopamine receptors. This engages mechanisms that influence the concentration of specific mediators, particularly within brainstem nuclei that regulate emetic reflexes.

Dosage and Administration Information

Codopalm (Promethazine hydrochloride) administration is governed by specific guidelines detailing the approved routes and required procedural conditions. The medicine is commonly utilized through oral formulations, such as tablets and syrup, or via the rectal route using suppositories. For scenarios requiring a parenteral approach, deep intramuscular (IM) injection is the preferred method of administration.

Dosing regimens for adults generally range from 12.5 mg to 50 mg per single dose, depending on the acute context. Dosing frequency follows patterns of either once daily (often taken at night) or an as-needed (PRN) schedule, repeated every 4 to 6 hours, while respecting established 24-hour total dose limits. Oral doses may be taken with food or milk to potentially lessen gastrointestinal discomfort.

Special handling rules apply to injectable forms. The intravenous (IV) route requires mandatory dilution to a concentration no greater than 1 mg/mL, and the infusion rate must not exceed 25 mg/minute. Furthermore, Codopalm is contraindicated for use in children under 2 years of age for any indication. For children 2 years and older, dosing is determined by weight, using the lowest effective amount, as the medicine is generally intended for short-term or intermittent use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Codopalm

Evidence for Use in Symptomatic Relief of Cough Associated with Upper Respiratory Conditions

Research has been conducted to explore Codopalm’s use in conditions where symptoms may vary in intensity, such as cough associated with upper respiratory issues. Studies were typically short-term randomized controlled trials (RCTs). Researchers monitored outcomes related to outcomes describing episodic or acute changes, such as the frequency of coughing events and patient-reported outcomes describing perceived discomfort using standardized severity scales.

The findings describe patterns observed in the studies over the short-term study period. Research highlights changes measured in patient reports regarding the severity of their cough. These findings help contextualize how patients reported their experience of acute cough and contribute to the broader evidence landscape for the condition studied.

Comparison to Placebo and Other Treatments

Studies have explored how Codopalm compares to receiving an inactive pill (a placebo) or another approved treatment. Comparative evidence is lacking for some of the common formulations, meaning not all combinations have been tested head-to-head against every other treatment option.

Evidence for Use in Mild-to-Moderate Pain Management (Adjuvant Analgesia)

For the management of mild-to-moderate pain, the drug components was evaluated in research scenarios focusing on acute, temporary pain, such as after surgical procedures. The evidence is mainly derived from Phase 3 clinical trials where groups of patients receiving the study drug were compared to control groups receiving a placebo. Research examined outcomes related to physical discomfort, specifically focusing on measured changes in pain intensity over a limited timeframe, typically 24 to 48 hours.

Data show patterns related to differences in pain intensity measurements between the study groups and control groups during the initial acute phase. Studies monitored the time it took for some patients to require additional pain medication. These results apply only to the populations studied—that is, patients experiencing acute, immediate pain—and do not provide information regarding outcomes for chronic pain.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Codopalm (FAQ)

Q: How long does it typically take for Codopalm to start having an effect?

The effects of the promethazine component are generally apparent within 20 minutes after taking the medicine by mouth. The codeine component, which modulates afferent signaling, may begin to have an effect within 15 to 30 minutes after oral use.

Q: Is there a known withdrawal period when stopping Codopalm?

Regulatory-approved patient information suggests that if this medicine is used for a long duration and then stopped suddenly, some people may experience symptoms. These can include feelings of dizziness, sweating, or sickness, and trouble sleeping. Discontinuation should be discussed with a healthcare provider.

Q: Are there any risks associated with using Codopalm long-term?

Official product information notes this medicine is generally intended for short-term or intermittent use only. Official information states that prolonged administration of medicines containing phenothiazines is associated with the risk of developing tardive dyskinesia, which involves involuntary movements.

Q: Are there different forms (like liquid vs. tablet) that Codopalm comes in?

According to official documents, Codopalm is available in several formulations to allow for different routes of use. These commonly include oral solution (syrup), tablets, suppositories for rectal use, and a sterile preparation for deep intramuscular injection.

Q: Are the effects of Codopalm consistent across different patient populations?

Official documents indicate that the effects may vary across different populations. For instance, older adults may have heightened sensitivity to the medicine’s adverse effects. Children require specific caution and dosing due to increased risk of serious adverse reactions, indicating that the official guidance is different for these age groups.

Q: Is it true that Codopalm is used only for severe cases of the condition it treats?

The research evidence examined its use for symptomatic relief of cough and in the management of mild-to-moderate pain, supporting its application beyond only severe cases. Official indications specify the uses for which the drug has regulatory approval.

Q: Does Codopalm require a prescription everywhere?

As a combination product containing Codeine, official regulatory bodies classify it as a Schedule V controlled substance. This classification means the medicine is subject to specific federal restrictions on dispensing in regulated health systems.

Q: What is the relevance of the 'Pharmacodynamics' section in the official document for a patient?

The 'Pharmacodynamics' section describes the drug's mechanism of action—that is, how it works at a molecular level in the body. This information helps explain the biological basis for the medicine's therapeutic effects and the reasons behind its side effects, such as the sedating and anti-nausea actions.

Q: What is the maximum duration of use described in clinical trials?

Official guidance emphasizes that the drug is generally intended for short-term or intermittent use. Dosing limits are established based on short timeframes, such as the maximum total dose allowed within a 24-hour period, which aligns with its intended use for acute symptoms.

Q: Does Codopalm interact with common cold or flu medicines?

Official drug interaction warnings indicate that the medicine can interact with other drugs that cause central nervous system depression or drowsiness. This includes many over-the-counter cold and flu preparations that contain sedating ingredients, such as certain antihistamines.

Q: Are there genetic factors that might influence how Codopalm works for someone?

Regulatory information related to the Codeine component notes that some individuals convert Codeine into its active form, morphine, more rapidly or slowly than others. This difference in metabolism is related to genetic factors and can influence how the medicine may work.

Q: What are the legal age restrictions for prescribing Codopalm?

Official documents place stringent age restrictions on the use of this medicine for certain indications. For example, for cough and upper respiratory symptoms, the combination product is not indicated for pediatric patients under 18 years of age, and its use is formally contraindicated in children below a specific younger age.

Q: Are there known effects of Codopalm on fertility?

Based on regulatory-approved patient information, there is currently no evidence that the promethazine component affects fertility in men or women. This information is based on the available data reviewed by official bodies.

Q: Is Codopalm the same type of medication as other drugs used for similar conditions?

The medicine is officially classified as a first-generation antihistamine and a phenothiazine derivative. This classification helps define its general type, noting that it belongs to a class of medicines known for significant central nervous system and sedating effects, which differentiates it from other drug classes.

Q: Can Codopalm affect sleep patterns?

While official information states the medicine causes pronounced sedation, official information indicates that the promethazine component may influence sleep architecture. Research suggests it may increase total sleep time but may also reduce the percentage of time spent in REM sleep.

Q: What over-the-counter pain relievers can potentially interact with Codopalm?

Official drug interaction warnings caution against using other central nervous system depressants. This includes over-the-counter pain relievers that contain opioids or certain sedating antihistamines, which increase the risk of adverse effects like excessive drowsiness.

Q: Can Codopalm be used safely with common vitamins or supplements?

Official guidance advises that a healthcare provider should be informed of all prescription drugs, over-the-counter medicines, and herbal supplements. This is because some non-prescription products may increase the risk of adverse effects, such as drowsiness, when combined with this medicine.

Q: Has Codopalm been studied in children or adolescents?

The medicine's use is highly restricted in patients under 18 years of age due to safety concerns and regulatory warnings. However, clinical guidelines exist for limited short-term use in children aged 2 years and older, indicating that evidence has been examined to support its restricted application in those age groups.

Q: Does Codopalm cause any known issues with driving or operating machinery?

Regulatory safety statements explicitly constrain the medicine's use in situations requiring full mental alertness and physical coordination. This is due to its pronounced sedative nature, which may impair the ability to drive or safely operate complex machinery.

Q: Does Codopalm have a generic version available?

The key active ingredient, promethazine hydrochloride, is widely available in generic form. As a combination product, it is manufactured by different companies and may also be available generically in various formulations.

How should Codopalm be stored and disposed of?

Official Storage and Disposal Requirements

Codopalm (Promethazine hydrochloride) must be stored strictly according to regulatory labeling to maintain product stability and safety.

Storage Conditions

The medicine requires storage at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The product must be protected from freezing and protected from light. It is mandatory to store the medicine in the original container, keep the container tightly closed, and place it out of the sight and reach of children.

Disposal Instructions

Unused or expired product should be disposed of using drug take-back programs, which are the preferred method according to regulatory guidelines. If a take-back program is unavailable, the medicine must be mixed with an unappealing substance, sealed in a bag, and placed in household trash; it must not be discarded into wastewater (sinks or toilets).

Codopalm